Job Watch

Paramount Recruitment: Python Software Engineer - Bioinformatics

New Scientist - Bioinformatics - Tue, 2018-02-13 11:46
Negotiable: Paramount Recruitment: Python Software Engineer - Bioinformatics A superb new opportunity has become available for a talented Python Developer to work with a growing Biotech based in Cambridge. Cambridge, England
Categories: Job Watch

Administrative Supplement for Research on Sex/Gender Influences (Admin Supp - Clinical Trial Optional)

Funding Opportunity PA-18-658 from the NIH Guide for Grants and Contracts. The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex/gender influences in human health and illness, including basic, preclinical, clinical, translational, and behavioral studies. Of special interest are studies relevant to understanding the significance of biological sex on cells and tissue explants; comparative studies of male and female tissues, organ systems and physiological systems; sex-based comparisons of pathophysiology, biomarkers, gene expression, clinical presentation and prevention and treatment of diseases. The most robust experimental designs include consideration of both sex and gender; therefore, applications proposing to investigate the influence of both sex and gender factors are highly encouraged. The proposed research must address at least one objective from Goals 1 through 3 of the NIH Strategic Plan for Women's Health Research.

Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)

Funding Opportunity PAR-18-657 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54s). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of the research includes target and candidate identification and characterization, through candidate optimization and demonstration of in vivo efficacy consistent with the product's intended use in humans. For applicants submitting U54 renewal applications, research under this FOA should culminate in an optimized lead compound ready for advanced development. The Centers will contain at least three research projects supported by an administrative core, up to three optional scientific cores, and a research education core. Each research project must include milestones that create discrete go or no-go decision points in a progressive translational study plan.

NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

Funding Opportunity PAR-18-656 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include traditional clinical trials meant to develop and test behavior change interventions meant to prevent or treat dental, oral, or craniofacial conditions, as well as interventions that are used as tools to understand mechanisms of behavior change. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase for behavioral and social intervention clinical trials will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents such as the Manual of Procedures for the subsequent clinical trial in the UH3 phase. The UH3 phase of the award will support the conduct of investigator-initiated intervention research at all stages, from early mech

Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)

Funding Opportunity PAR-18-655 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

Basic Research in Cancer Health Disparities (R01 Clinical Trials Not Allowed)

Funding Opportunity PAR-18-654 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

Paramount Recruitment: Python Developer - London - Bioinformatics

New Scientist - Bioinformatics - Tue, 2018-02-13 05:11
Negotiable: Paramount Recruitment: Python Developer - Bioinformatics London Paramount are working in partnership with Genomics England to expand their team in order to deliver success Paramount are working in partnership with Genomics England to expand their team in order to with the 100, London, England
Categories: Job Watch

Computational Immunologist, Antigen Map - Adaptive Biotechnologies - Seattle, WA

Indeed.com - Bioinformatics - Tue, 2018-02-13 01:39
Quickly develop and implement prototype data analysis pipelines to keep pace with wet-lab advances, while building toward a scalable and efficient analysis...
From Adaptive Biotechnologies - Tue, 13 Feb 2018 06:39:55 GMT - View all Seattle, WA jobs
Categories: Job Watch

RESEARCH DATA SCIENTIST - University of Wisconsin–Madison - Madison, WI

Indeed.com - Bioinformatics - Mon, 2018-02-12 18:12
Training and or/experience in machine learning, data science, statistics, and/or data visualization. They will be responsible for designing novel algorithms and...
From University of Wisconsin–Madison - Mon, 12 Feb 2018 23:12:40 GMT - View all Madison, WI jobs
Categories: Job Watch

Paramount Recruitment: Bioinformatics Analyst

New Scientist - Bioinformatics - Mon, 2018-02-12 09:48
Negotiable: Paramount Recruitment: Bioinformatics Analyst A fantastic opportunity has become available for a talented Bioinformatics Analyst to join some of the world's brightest minds at one of the country's most influential Biotechs. Headquartered at an idyllic location in Cambridge, Cambridge, England
Categories: Job Watch

Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults (R01 Clinical Trial Optional)

Funding Opportunity PA-18-651 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement encourages developmentally tailored research focused on adolescents and emerging adults as it relates to HIV prevention and treatment. Research is encouraged to incorporate recent advances in adolescent and young adult developmental research to optimize outcomes in HIV prevention and care research for this heterogeneous population. PA-FY-NNN uses the R01 grant mechanism, PA-FY-NNN uses the R21 mechanism, while PA-FY-NNN uses the R34 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants with preliminary data and/or planning to include longitudinal analysis may wish to apply using the R01 mechanism. Applicants wanting to develop and pilot test an intervention may wish to apply using the R34 mechanism.

Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults (R21 Clinical Trial Not Allowed)

Funding Opportunity PA-18-652 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement encourages developmentally tailored research focused on adolescents and emerging adults as it relates to HIV prevention and treatment. Exploratory research is encouraged to incorporate recent advances in adolescent and young adult developmental research to better understand HIV prevention and care of this heterogeneous population. PA-FY-NNN uses the R01 grant mechanism, PA-FY-NNN uses the R21 mechanism, while PA-FY-NNN uses the R34 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants with preliminary data and/or planning to include longitudinal analysis may wish to apply using the R01 mechanism. Applicants wanting to develop and pilot test an intervention may wish to apply using the R34 mechanism

Pages

Subscribe to Anil Jegga aggregator - Job Watch